Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety

BACKGROUND: Melatonin is extensively used in the USA in a non-regulated manner for sleep disorders. Prolonged release melatonin (PRM) is licensed in Europe and other countries for the short term treatment of primary insomnia in patients aged 55 years and over. However, a clear definition of the targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Wade, Alan G, Ford, Ian, Crawford, Gordon, McConnachie, Alex, Nir, Tali, Laudon, Moshe, Zisapel, Nava
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933606/
https://www.ncbi.nlm.nih.gov/pubmed/20712869
http://dx.doi.org/10.1186/1741-7015-8-51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933606/
https://www.ncbi.nlm.nih.gov/pubmed/20712869
http://dx.doi.org/10.1186/1741-7015-8-51

Ejemplares similares